Scarica l'app Stockscreener
4.22
4.31%
-0.19
Dopo l'orario di chiusura:
4.19
-0.03
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - Yahoo Finance
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Reports Positive ATI-052 Phase 1a Trial Results - TipRanks
Aclaris reports phase 1a trial results for ATI-052 antibody By Investing.com - Investing.com Canada
Aclaris Therapeutics announced that the Phase 1B clinical trial of its drug candidate ATI-052 is currently actively recruiting patients. - Bitget
Aclaris (NASDAQ: ACRS) touts ATI-052 data, targets lichen planus with ATI-2138 - Stock Titan
Aclaris targets lichen planus, a disease with no approved therapies - Stock Titan
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing - marketscreener.com
Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock - Investing.com
Aclaris Therapeutics (NASDAQ: ACRS) insider-linked fund sells 300,000 shares - Stock Titan
BML Investment lists 13.95M shares (9.9%) in Aclaris (NASDAQ: ACRS) - Stock Titan
Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday By Investing.com - Investing.com Canada
Aclaris Therapeutics to Announce Phase 1a Trial Results for ATI-052 and Lead Indication Selection for ATI-2138 on April 28, 2026 - Quiver Quantitative
What Aclaris will reveal Tuesday on two immune-disease drug programs - Stock Titan
Aclaris Therapeutics (ACRS) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - Sahm
Aclaris Therapeutics (ACRS) Proxy filing Summary - Quartr
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap DownHere's What Happened - MarketBeat
Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, board elections in Aclaris Therapeutics (NASDAQ: ACRS) 2026 proxy - Stock Titan
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Aclaris (ACRS) Stock Gap Down Watch (Investor Interest) 2026-04-20Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai
Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN
ACRS Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target - Moomoo
Oppenheimer initiates Aclaris stock with Outperform rating By Investing.com - Investing.com Australia
Oppenheimer initiates Aclaris stock with Outperform rating - Investing.com
H.C. Wainwright reiterates Aclaris stock rating on drug trial data By Investing.com - Investing.com Canada
Aclaris (ACRS) Stock: Momentum Shift (Marginal Gain) 2026-04-15Fast Rising Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming - Yahoo Finance
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4% - MarketBeat
Market Overview: What is the implied volatility of Aclaris Therapeutics Inc2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Is Aclaris (ACRS) Stock Attractive Now | Price at $4.00, Down 1.11%Turnaround Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Pullback Watch: Will Aclaris Therapeutics Inc benefit from AI trends2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
ACRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Sahm
Is Aclaris (ACRS) Stock Near a Bottom | Price at $3.98, Up 0.76%Price Surge - Xã Châu Thành
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance UK
Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts - National Today
RA Capital Group reports 7.63M Aclaris shares (NASDAQ: ACRS) - Stock Titan
Forecast Cut: Why is Aclaris Therapeutics Inc stock going upMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - MarketBeat
ACRS Stock Analysis: Aclaris Therapeutics Inc biotech stock gains 1.45 percent at 4.2 dollars - UBND thành phố Hải Phòng
Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
ACRS SEC FilingsAclaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat
Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):